PROVECTUS BIOPHARMACEUTICALS, INC. 4
4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Mar 31, 2016
Insider Transaction Report
Form 4
Koe Jan
Director
Transactions
- Exercise Out-of-Money
Common Stock
2016-03-29$1.25/sh+100,000$125,000→ 786,300 total - Exercise Out-of-Money
Common Stock Warrants (right to buy)
2016-03-29−100,000→ 0 totalExercise: $1.25From: 2012-06-28Exp: 2016-04-15→ Common Stock (100,000 underlying) - Exercise Out-of-Money
Common Stock Warrants (right to buy)
2016-03-29−100,000→ 0 totalExercise: $1.25From: 2011-04-20Exp: 2016-04-20→ Common Stock (100,000 underlying) - Exercise Out-of-Money
Common Stock
2016-03-29$1.25/sh+100,000$125,000→ 686,300 total - Exercise Out-of-Money
Common Stock Warrants (right to buy)
2016-03-29+100,000→ 100,000 totalExercise: $0.85From: 2016-03-29Exp: 2020-06-19→ Common Stock (100,000 underlying) - Exercise Out-of-Money
Common Stock Warrants (right to buy)
2016-03-29+100,000→ 100,000 totalExercise: $0.85From: 2016-03-29Exp: 2020-06-19→ Common Stock (100,000 underlying)
Holdings
- 150,000(indirect: By LLC)
Common Stock
Footnotes (1)
- [F1]On March 29, 2016, the reporting person exercised an aggregate of 200,000 warrants pursuant to the Issuer's warrant exchange offer, at a discounted exercise price of $0.50 per share, which exercise consisted of: (i) an exercise of 100,000 shares pursuant to a warrant issued on June 28, 2012, with an original exercise price of $1.25 per share and (ii) an exercise of 100,000 shares pursuant to a warrant issued on September 20, 2013, with an original exercise price of $1.25 per share. Under the terms of the warrant exchange offer, holders received, in addition to the common stock acquired upon exercise of their existing warrants, an equal number of new warrants to purchase the same number of shares of the Issuer's common stock at an exercise price of $0.85 per share that will expire June 19, 2020.